A Multicentre, Parallel-group, Phase IIb, Randomised, Double-blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO)
Latest Information Update: 26 Aug 2025
At a glance
- Drugs AZD 6793 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms PRESTO
- Sponsors AstraZeneca
Most Recent Events
- 01 Aug 2025 New trial record